A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2013
This article has no abstract
Epistemonikos ID: 727d53918e1a2f098b3db506d6503d3bb496888a
First added on: Feb 05, 2025